Use of menACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: Recommendations of the advisory committee on immunization practices, 2013

Morbidity and Mortality Weekly Report

Volumn , Issue 24, 2014, Pages 527-530

  MacNeil, Jessica R ^a   Rubin, Lorry ^c   McNamara, Lucy ^b   Briere, Elizabeth C ^a   Clark, Thomas A ^a   Cohn, Amanda C ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

MENACWY CRM VACCINE; MENACWY-CRM VACCINE; MENINGOCOCCUS VACCINE;

ADVISORY COMMITTEE; ARTICLE; HUMAN; IMMUNIZATION; INFANT; LICENSING; MENINGOCOCCOSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STANDARD; UNITED STATES;

ADVISORY COMMITTEES; HUMANS; IMMUNIZATION; IMMUNIZATION SCHEDULE; INFANT; LICENSURE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; UNITED STATES;

EID: 84902595922     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. CDC. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR 2011;60:1391–2.
2. CDC. Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR 2013;62:52–4.
3. CDC. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2013;62(No. RR-02).
4. Klein NP, Reisinger KS, Johnston W, et al. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J 2012;31:64–71.
5. Klein NP, Shepard J, Bedell L, Odrljin T, Dull P. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine 2012;30:3929–36.
6. Tregnaghi M, Tregnaghi M, D’Andrea U, Grana MG, Dull P, Bedell L. Immunogenicity of a quadrivalent MenACWY-CRM conjugate vaccine administered in various schedules to Argentinian infants and toddlers. Abstract presented at the 29th meeting of the European Society for Paediatric Infectious Diseases; The Hague, Netherlands; June 7–11, 2011.
7. Nolan TM, Nissan MD, Naz A, et al. Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age. Hum Vaccin Immunother 2014;10:280–9.
8. Abdelnour A, Silas PE, Lamas MR, et al. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: Results of an open-label, randomized, phase 3b controlled study in healthy infants. Vaccine 2014;32:965–72.
9. Ahmed F, Temte J, Campos-Outcalt D, Schunemann H, ACIP Evidence Based Recommendations Work Group. Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). Vaccine 2011;29:9171–6.
10. Cooper B, DeTora L, Stoddard J. Menveo: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev Vaccines 2011;10:21–33.
11. Food and Drug Administration. Package insert: Menveo (meningococcal (groups A, C, Y and W-135)) oligosaccharide diphtheria CRM197 conjugate vaccine, Novartis Vaccines and Diagnostics, Inc. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2013. Available at http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm201349.pdf.
12. CDC. Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease—Advisory Committee on Immunization Practices (ACIP), 2011. MMWR 2011;60:1018–9.